Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Thursday

Upstream Bio (NASDAQ:UPBGet Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect Upstream Bio to post earnings of ($0.62) per share for the quarter.

Upstream Bio (NASDAQ:UPBGet Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($6.96) EPS for the quarter, missing the consensus estimate of ($0.58) by ($6.38). The business had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.83 million. On average, analysts expect Upstream Bio to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Upstream Bio Trading Up 4.1 %

NASDAQ:UPB opened at $10.25 on Thursday. The stock’s 50 day moving average is $16.86. Upstream Bio has a fifty-two week low of $9.29 and a fifty-two week high of $29.46.

Wall Street Analyst Weigh In

Several equities research analysts have commented on UPB shares. TD Cowen began coverage on Upstream Bio in a research note on Tuesday, November 5th. They set a “buy” rating for the company. William Blair assumed coverage on shares of Upstream Bio in a research report on Tuesday, November 5th. They issued an “outperform” rating for the company. Piper Sandler started coverage on Upstream Bio in a report on Tuesday, November 5th. They set an “overweight” rating and a $75.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on Upstream Bio in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $38.00 target price on the stock.

View Our Latest Research Report on UPB

About Upstream Bio

(Get Free Report)

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.

Featured Articles

Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.